<DOC>
	<DOCNO>NCT01056848</DOCNO>
	<brief_summary>To evaluate overall safety continue efficacy oral lixivaptan capsule subject euvolemic hypervolemic hyponatremia</brief_summary>
	<brief_title>International , Multicenter Study Twenty-eight Week , Open-label , Titrated Oral Lixivaptan Administration Patients With Chronic Hyponatremia : Extension Studies CK-LX3401 , 3405 , 3430</brief_title>
	<detailed_description>Phase I Phase II clinical trial demonstrate lixivaptan may play important role treat hyponatremia sign symptom water retention associate HF , LCWA SIADH . Lixivaptan previously evaluate disease state characterize hyponatremia euvolemia ( SIADH ) hyponatremia combine fluid overload ( HF , LCWA ) . Lixivaptan demonstrate correction serum sodium concentration together mark aquaresis patient hyponatremia .</detailed_description>
	<mesh_term>Hyponatremia</mesh_term>
	<criteria>1 . Men woman 18 year age old 2 . Ability provide inform consent assent 3 . Prior participation lixivaptan hyponatremia trial evidence continue need desire therapy 1 . A current medical condition longterm treatment aquaretic agent may present undue risk patient 2 . Hyponatremia acute , reversible , artificial due condition associate vasopressin excess likely respond aquaretic therapy 3 . Hyponatremia due reversible medical condition therapy 4 . Conditions associate independent imminent risk morbidity mortality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Euvolemic Hyponatremia</keyword>
	<keyword>Hypervolemic Hyponatremia</keyword>
	<keyword>SIADH</keyword>
	<keyword>Serum Sodium</keyword>
</DOC>